These mice develop almost simultaneously IGF2-dependent rhabdomyosarcoma and IGF2-independent salivary carcinoma, thus allowing to evaluate the specificity of anti-IGFs treatment. The gene discussed is IGF2; the disease is rhabdomyosarcoma.